Phase III Study of Carboplatin and Paclitaxel Alone or With Sorafenib in Advanced Non–Small-Cell Lung Cancer
Giorgio V. Scagliotti(Ospedale San Luigi Gonzaga), Nasser H. Hanna(Ontario Institute for Cancer Research), Osvaldo Rudy Aren(Dnipro State Medical University), Maria Csollak(Alleanza Contro il Cancro), Lisa Cupit(Alleanza Contro il Cancro), Joachim von Pawel(Asklepios Fachkliniken München-Gauting), Francesco Grossi(University of Insubria), Martin Reck(German Center for Lung Research), Maciej Krzakowski(The Maria Sklodowska-Curie National Research Institute of Oncology), Frank Cihon(Alleanza Contro il Cancro), István Albert(Alleanza Contro il Cancro), Michael Thomas, Carlos H. Barrios(Eastern Cooperative Oncology Group), José Rodrigues Pereira, Beatrix Bálint(Alleanza Contro il Cancro), Alan Keller(Alleanza Contro il Cancro), José Elias Miziara(Alleanza Contro il Cancro), Silvia Novello(University of Turin), Sandra DiMatteo(Alleanza Contro il Cancro), Filippo de Marinis(Carlo Forlanini Hospital)
Cited by 454
Related Papers
Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial
|The Lancet Oncology|2012|5.5k
International Association for the Study of Lung Cancer/American Thoracic Society/European Respiratory Society International Multidisciplinary Classification of Lung Adenocarcinoma
|Journal of Thoracic Oncology|2011|4.8k
Atezolizumab versus docetaxel in patients with previously treated non-small-cell lung cancer (OAK): a phase 3, open-label, multicentre randomised controlled trial
|The Lancet|2016|4.8k
First-Line Atezolizumab plus Chemotherapy in Extensive-Stage Small-Cell Lung Cancer
|New England Journal of Medicine|2018|3.5k
Crizotinib versus Chemotherapy in Advanced <i>ALK</i> -Positive Lung Cancer
|New England Journal of Medicine|2013|3.4k